GLP-1 Drugs After 65: Strength, Not Just Weight

The reassuring finding about muscle comes from trials in general adult populations, and it is real: handgrip strength has held up in short and medium-term trials of semaglutide and liraglutide even while lean soft tissue fell.^[1] The trouble is that the picture changes in the group most likely to be harmed by it. Longitudinal and retrospective research in older adults with type 2 diabetes reports the opposite — reduced grip strength and accelerated sarcopenia with prolonged semaglutide use.^[1] There are still no dedicated guidelines for prescribing these drugs after 65.^[3]

Mass and strength are not the same measurement

Most of the argument about muscle on these drugs is really about mass, because mass is what a DXA scanner measures and what body-composition substudies report. Our lean mass article works through that evidence, and the short version is more reassuring than the headlines: lean tissue accounts for roughly a quarter to a third of weight lost, and intensive lifestyle programs cost a comparable share.

Strength is a different variable. It is what decides whether someone can rise from a chair without using their arms, carry shopping, or recover a stumble instead of falling. Grip strength is the standard proxy, and it is one of the defining components of sarcopenia rather than a stand-in for size.

A scanner can tell you how much muscle is left. It cannot tell you what that muscle can still do.

What the strength evidence shows, by age

Two things separate the last row from the first. One is age, and the fact that muscle mass and strength are already declining before any drug is involved. The other is duration: the reassuring results come from short and medium-term trials, and the concerning ones from prolonged use. A treatment intended to continue indefinitely is not well described by a 68-week trial.

Who carries the most risk

A 2025 review looked at the groups already predisposed to sarcopenia before a GLP-1 enters the picture, and made the obvious but under-stated point: the same proportional loss lands harder on someone with less reserve.^[2] It puts lean mass at as much as 15 to 40% of total weight lost, and notes that evidence on body composition is insufficient in older adults, and equally so in chronic kidney disease, liver disease and inflammatory bowel disease.

• Anyone already frail, or recently hospitalized. Reserve is the variable, not percentage lost.
• Anyone with sarcopenic obesity — high fat and low muscle together, which is common after 65 and easy to miss because the scale looks like a straightforward obesity problem.^[3]
• Anyone eating substantially less than they were. Appetite suppression that works is appetite suppression that can undercut protein intake at exactly the age it matters most.
• Anyone not doing resistance work. The reviews agree on this even where they agree on little else.

What is actually recommended, and by whom

This is the gap. A 2024 review of obesity pharmacotherapy in adults 65 and over found the general-population efficacy and safety data increasingly favorable — and concise guidelines for older adults simply unavailable.^[3] It calls for trials that measure geriatric outcomes rather than weight alone.

So a prescriber weighing this for someone in their seventies is extrapolating from trials whose average participant was decades younger, without a guideline to work from. That is not a reason to withhold an effective drug from an older patient. It is a reason to know that the usual scaffolding is missing, and to ask what is being monitored instead.

What the reviews do converge on is unglamorous and consistent: adequate protein, and resistance training, from the start rather than after a loss.^[2] Our protein calculator works a target from body weight, and the exercise pairing tool sets out the training side. For the same question framed around the menopausal transition rather than age 65, see GLP-1 drugs after menopause.